Abstract: A luggage dolly for supporting and moving a luggage article includes a first panel and a second panel, each of which has a top surface, a bottom surface, a front edge surface, a rear edge surface, a pair of side edge surfaces, and a pair of wheels. A coupler is designed to couple the first panel and the second panel to support an end wall of a luggage article. A projection projects from the front edge surface of the first panel. The projection is insertable under a handle loop projecting from the end wall of the luggage article and into engagement with the second panel to secure the first panel and the second panel to the handle loop with ends of the handle loop positioned in a pair of spaces between the front edge surface of the first panel and the front edge surface of the second panel.

Abstract: A support rod storage securing system includes a container for holding clothing that has a bottom wall and a perimeter wall that is attached to and extending upwardly from the bottom wall. The perimeter wall has an upper edge defining an opening extending into the container. A frame member is mounted to the container. A collapsible dressing station is removably mountable to the container such that the collapsible dressing station extends upwardly from the container. The collapsible dressing station includes an upper bar configured to receive clothes hangers. A pair of connectors each is attached to the frame member. The upper bar is removably mounted on the pair of connectors such that the upper bar is releasably retained in a static position within the container.

Abstract: A system and a method for indexing pedestrian traffic are disclosed. Traffic information is gathered from counter units (30, 31) placed at entrances in provider malls, retail stores, or other locations where pedestrians may be counted. The counters give daily reports to the traffic indexing system (40) of the amount of pedestrian traffic flowing through traffic monitoring points (30, 31). Traffic data are collected daily from providers and compiled into an index (40). These data may be integrated and indexed with other data such as sales data, labor data and promotion data. Providers (30, 31) and other users (45) may access the traffic index (40) along with other industry information to gauge their performance as compared to the performance of others in the industry or to make educated decisions on development and marketing issues.

Abstract: Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example being IL-10. These immunoregulatory activities of Cpn10 may be useful in the treatment of diseases, disorders and conditions resulting from excessive pro-inflammatory cytokine and chemokine secretion. This invention also relates to producing, designing and/or screening Cpn10 agonists and antagonists according to their ability to regulate Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion.

Abstract: A composition for nasal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient. The invention also provides a composition for buccal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient to form a solid dosage form, wherein the solid dosage form disintegrates in an oral cavity at body temperature and may adhere to body tissue of the oral cavity; a composition for pulmonary administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient; and, a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject.

Abstract: A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof; a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline; and, various methods of manufacturing or forming an immediate dosage form of varenicline.

Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

Abstract: This invention relates to a powder for oral suspension, and an oral suspension made therefrom, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin. This invention further relates to a method for reducing the conversion of a form of non-dihydrate azithromycin, in an oral suspension, by adding a surface tension reducing excipient that reduces the surface tension of the aqueous vehicle. Furthermore, this invention relates to a method for reducing the conversion of a non-dihydrate azithromycin, in an unflavored oral suspension, by raising the viscosity of the oral suspension, and in a flavored oral suspension by lowering the viscosity of the oral suspension.

Abstract: This invention provides a urine leg drainage bag supporter comprising a waist encircling belt; a pouch for holding a urine bag, the pouch being formed of front and back panels connected at the vertical edges to define an opening in the top and bottom portions of the pouch, the front panel being formed of a stretchable material to firmly hold the bag within the pouch; a plurality of vertical straps connecting the pouch to the belt; and a plurality of horizontal straps extending from the pouch for encircling the leg of the wearer.